Outbidding 14 others and then themselves: How Amgen spent $2 billion on a biotech that had been on the brink - Endpoints News

nomporkin.blogspot.com

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

After a slow couple of weeks, the biotech IPO market is heating back up with four more companies hitting Nasdaq.

Instil Bio, Connect Biopharma, Finch Therapeutics and Gain Therapeutics are this week’s winners, with the fearsome foursome all making their public debuts Thursday or Friday. Instil led the way with a heavily upsized $320 million raise, marking the second-biggest IPO raise of 2021 behind Sana, and Connect and Finch also pulled in nine-figure funding.

Let's block ads! (Why?)

Article From & Read More ( Outbidding 14 others and then themselves: How Amgen spent $2 billion on a biotech that had been on the brink - Endpoints News )
https://ift.tt/2OMmyYo
Business

Bagikan Berita Ini